A complete portfolio of vaccines that deliver robust efficacy with a proven safety profile<\/p>\n\n\n\n\n\n\n\n\n
\u201cQuote from testimonial video\u201d<\/em><\/p>\n\n\n\n\n\n\n\n\n\n \u201cQuote from testimonial video\u201d<\/em><\/p>\n\n\n\n\n\n\n\n\n\n \u201cBy triggering a robust antibody and cellular immune response without the use of an adjuvant, RNA particle technology offers an innovative way to deliver next-level protection for cats for FeLV.\u201d<\/em><\/p>\n\n\n\n\n\n\n\n\n\n \u201cBy triggering a robust antibody and cellular immune response without the use of an adjuvant, RNA particle technology offers an innovative way to deliver next-level protection for cats for FeLV.\u201d<\/em><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination. <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day<\/strong>, occurring 10 days after the second vaccination.\u00a0<\/p>\n\n\n\n\n\n\n\n\n\n\n\n One kitten in the test group experienced a mild adverse event consisting of reduced activity for one day, occurring 10 days after the second vaccination. <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\nTestimonial Video 02<\/strong><\/h3>\n\n\n\n
Testimonial video 03<\/strong><\/h3>\n\n\n\n
Testimonial video 0<\/strong>4<\/h3>\n\n\n\n
Laboratory overdose\/repeat-dose studies1<\/sup><\/h2>\n\n\n\n\n\n\n<\/span>\n\n\n\n\n\n\n\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.<\/h2>\n\n\n\n\n\n
Daily monitoring of:<\/h2>\n\n\n\n
\n
Results1<\/sup><\/h3>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n
\n
Field Study<\/h2>1<\/sup>\n\n\n\n\n\n\n<\/span>\n\n\n\n\n\n\n\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Safety was assessed in a \ufb01eld study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen – 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.<\/h2>\n\n\n\n\n\n
Daily monitoring of:<\/h2>\n\n\n\n
\n
Results1<\/sup><\/h3>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n
\n
Laboratory overdose\/repeat-dose studies1<\/sup><\/h2>\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.<\/h2>\n\n\n\n
Daily monitoring of:<\/strong><\/h2>\n\n\n\n
\n
Results1<\/sup><\/h3>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n
\n
Field study1<\/sup><\/h2>\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Safety was assessed in a \ufb01eld study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen \u2013 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.<\/h2>\n\n\n\n
Daily monitoring of:<\/strong><\/h2>\n\n\n\n
\n
Results1<\/sup><\/h3>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n
\n
Laboratory overdose\/repeat-dose studies<\/h2>\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.<\/h2>\n\n\n\n
Daily monitoring of:<\/h2>\n\n\n\n
\n
Results<\/h2>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n\n
Field study<\/h2>\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Safety was assessed in a \ufb01eld study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen \u2013 71 healthy kittens (8 weeks old) and 71 healthy adult cats (>1 year old) of various (mixed) breeds allocated randomly to either test or control group.<\/h2>\n\n\n\n
Daily monitoring of:<\/h2>\n\n\n\n
\n
Results<\/h2>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n\n
STUDY DESIGN:<\/h2>\n\n\n\n
Studies in cats were performed to assess safety of a single and repeated dose (n=11 vaccinates, n=5 controls), two studies into safety of an overdose of viral components (n=10 vaccinates and n=11 vaccinates, n=5 controls, respectively) and a specific FPL overdose safety study (n=5). Studies used specific-pathogen-free kittens of 8 to 9 weeks of age.<\/h2>\n\n\n\n\n\n
Daily monitoring of:<\/h2>\n\n\n\n
\n
Results<\/h3>\n\n\n\n
No serious adverse events were observed in any of the studies.<\/h2>\n\n\n\n
\n
Nobivac NXT\u00ae HC<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n
Nobivac NXT\u00ae HCP<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n
Nobivac NXT\u00ae FeLV<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n
Nobivac NXT\u00ae HCPFeLV<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n
Nobivac NXT\u00ae HCPCh<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n
Nobivac NXT\u00ae HCPChFeLV<\/h3>\n\n\n\nLearn More<\/a>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
EURM-NOV-260600001<\/h5>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"editor_notices":[],"footnotes":""},"class_list":["post-151","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n